Previous 10 | Next 10 |
OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences. BioFlorida Conference Mr. Equels will be participating in the "...
AIM ImmunoTech (NYSE:AIM): Q3 GAAP EPS of -$0.08 in-line. Cash, cash equivalents and marketable securities of $53.7M Press Release For further details see: AIM ImmunoTech EPS in-line
OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021 Financial Highlights: As of September 30, 2021, AIM had cash, c...
OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Ph...
OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company’s belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19. ...
Finalizes and reports Phase 2 study protocol Expects to submit IND and apply for Fast Track Status with the FDA by October 18, 2021 Selects the Buffett Cancer Center and Erasmus MC as primary study sites OCALA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
OCALA, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:AIM) today announced that AIM and hVIVO have a signed Clinical Trial Agreement (CTA) for a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophylacti...
OCALA, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study the potential...
OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope spreading, cr...
OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion therapy for Post...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...